Clinical Trial Update: An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the efficacy and safety of Cofetuzumab Pelidotin in PTK7-expressing, recurrent non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cofetuzumab Pelidotin (cofetuzumab pelidotin)

Snippet

Sponsor: AbbVie | Conditions: Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING